Illustrative image – not actual.Sandesara groups Sterling Biotech plans to invest about Rs.600 crore to ramp up the manufacturing capacities of gelatine and coenzyme (Q10) at its facilities in Vadodara. The company is also considering increasing the manufacturing capacity of its recently acquired unit in China and is open to setting up greenfield facilities both in India and overseas.
The company will have capacity to produce 45 tonnes of Q10 by 2008 at their
Masar facility that was acquired from the Torrent group in 2005. They also plan
to invest about Rs.300 crore in phases to expand the facility that is producing
less than 10 tonnes of Q10. The work on the first phase with an investment of
Rs.120 crore has started.
Sterling Biotech plans to increase the
gelatine manufacturing capacity from 15,000 tonnes per annum to 22,000 tonnes
pa in next couple of years at its Vadodara facility. The company is considering
capacity expansion at their unit in China and replacement of machinery at Ooty
plant.
